This review provides an update on the need, development status, and important next steps for advancing development of vaccines against sexually transmitted infections (STIs), including herpes simplex virus (HSV), Neisseria gonorrhoeae (gonorrhea), Chlamydia trachomatis (chlamydia), and Treponema pallidum (syphilis).
Future Prospects for New Vaccines Against Sexually Transmitted Infections
HVTN 705 Vaccine Trial Ends—Join Sept 9 webinar to discuss next steps for field
Today Johnson & Johnson and partners announced that the Imbokodo study, a large-scale HIV vaccine proof-of-concept trial also known as HVTN 705/HPX2008, did not significantly reduce the overall risk of HIV acquisition among over 2,600 women in five sub-Saharan African countries. The Adenovirus26-based mosaic vaccine regimen was shown to be safe, but it did not meet pre-defined criteria for efficacy to warrant moving forward for longer follow-up. A companion study, the Phase III Mosaico trial, will continue.
Read AVAC’s full statement about the results and what needs to happen next.
Register for a global webinar, scheduled for September 9 at 10am ET to discuss this development and the implications for the HIV vaccine field.
We hope you will bring your questions and your passion. HIV continues to be a global threat. The field can and must learn from these trials and from the success of the COVID-19 vaccine enterprise, to explore new HIV vaccine strategies and bring a lasting end to the epidemic.
Press Release
HIV Vaccine Research Must Continue Following Disappointing Result from Imbokodo Trial
Underscores need for expanded access to proven, available HIV prevention options, says AVAC
Contact
Kay Marshall, +1 (347) 249-6375, kay@avac.org
New York City, August 31, 2021 – Today, Johnson & Johnson and partners announced that the Imbokodo study, a large-scale HIV vaccine proof-of-concept trial also known as HVTN 705/ HPX2008, did not significantly reduce the overall risk of HIV acquisition among over 2,600 women in five sub-Saharan African countries. The Adenovirus26-based mosaic vaccine regimen was shown to be safe, but it did not meet pre-defined criteria for efficacy to warrant moving forward for longer follow-up. A companion study, the Phase III Mosaico trial, will continue.
“AVAC recognizes the enormous contribution of the 2,637 women from five countries in Southern Africa who participated in the trial, and we congratulate the trial teams at sites and across the globe for their work on a superbly run study,” said Nandisile Luthuli, AVAC’s Regional Stakeholder Engagement Manager. “We applaud Johnson & Johnson for working in collaboration with the HIV prevention community, for their leadership in HIV vaccine research and for their longstanding commitment to Good Participatory Practices (GPP) that must be continued to maintain trust in vaccines and in research.”
“We always hope that efficacy trials will show positive results that lead directly to new prevention options,” said Mitchell Warren, Executive Director of AVAC. “It is very disappointing that this particular vaccine candidate did not work in this trial, but the trial was well-conducted and got an answer quickly. HIV remains a global threat, and a safe, efficacious and accessible HIV vaccine is still needed to contribute towards curbing new infections and providing a durable end to the pandemic.”
“This is in no way the end of the search for an HIV vaccine,” added Warren. “We still hope for a positive outcome from the ongoing Mosaico and PrEPVacc studies. Yet, now more than ever, the vaccine field needs diversity and creativity — and even more collaboration — in deciding what comes next as research priorities as there are no other vaccine candidates currently on a clear track to licensure. The field must focus on new hypotheses driven by this result and the recent antibody-mediated prevention study results, both of which showed some trends towards efficacy.”
“Just as decades of HIV research paved the way for effective COVID-19 vaccines, HIV vaccine developers now need to draw on the creativity, speed, agility and decision-making of COVID-19 vaccine development in product development, trial design and regulatory pathways,” said Stacey Hannah, AVAC’s Director of Research Engagement. “AVAC calls on donors, research groups and industry to join in strategic discussions with civil society and trial communities to map out a comprehensive strategy for the future of HIV vaccine research, product development and selection, and trial designs.”
A renewed commitment to this type of engagement within the HIV vaccine field would build on lessons learned from COVID-19 vaccine development and lead to a strategy that is coordinated, appropriately resourced, includes relevant target product profiles, and commits to share data across research groups and trials.
“For the last two decades, we have seen HIV prevention trials reporting annual incidence rates of four percent or higher among women trial participants in various East and Southern African countries. Sadly, Johnson & Johnson noted a high rate of HIV infections in this trial as well. There is a moral and ethical obligation to provide women living in contexts of HIV risk with prevention options that work for them,” added Warren. “The Imbokodo study is yet another stark reminder of the need to work harder and faster to roll out effective HIV prevention options at scale to the people who need them most, and to provide appropriate support to those using prevention options, even and especially within clinical trials.”
Safe and effective HIV prevention options, including male and female condoms, voluntary medical male circumcision and daily oral PrEP are all available now, but not rolled out to scale. Additional prevention options are nearing availability, including the Dapivirine Vaginal Ring and injectable cabotegravir, and several next-generation PrEP options are now entering advanced clinical trials.
“As the Imbokodo study participants return for their final visits, it is essential that they not only receive the research results, but are offered access to all available prevention options, including oral PrEP – which is available in all countries where the trial took place – and linked directly to these services,” added Luthuli. “In addition, the trial team and sponsors should explore innovative approaches to offering these trial participants the opportunity to enroll into new introduction projects offering the Dapivirine Vaginal Ring and injectable cabotegravir. The Imbokodo study team did a remarkable job of recruiting participants at high risk of HIV infection, and they now need to link the women to prevention options that work and can help them remain HIV-negative.”
The recent results of the HPTN 084 trial of injectable cabotegravir showed very low incidence rates among women in both the intervention arm and the comparative daily oral PrEP arm, making it clear that both forms of PrEP are effective prevention options. These options need to be taken to scale with urgency where they are most needed. In addition, going forward, AVAC calls for HIV prevention researchers, funders and sponsors to learn from the HPTN 084 success and better integrate these options into all future trials, even though this will require larger and more innovative trial designs.
The Imbokodo study evaluated whether an Adenovirus26-based mosaic vaccine regimen could safely and effectively reduce the rate of new HIV infections among 2,637 cisgender women in 23 sites in Malawi, Mozambique, South Africa, Zambia and Zimbabwe. Participants received a total of four doses over 12 months of either a prime-boost vaccine regimen of a mosaic viral-vectored vaccine, Adeno26.Mos4.HIV (Ad26 prime) and an aluminum phosphate-adjuvanted clade C gp140 protein (boost), or a placebo. Johnson & Johnson reported today in a press release that primary analysis of the data showed an efficacy estimate of 25.2 percent, but with a wide confidence interval that crossed zero (-10.5% to 49.3%). The press release also noted high HIV incidence rates among the women in the trial.
The Mosaico study uses a similar regimen with the same Ad26 platform for the prime vaccine, but using a different form of protein boost. The Phase III study, also known as HVTN 706/HPX3002, is currently enrolling 3,800 men and transgender people in eight countries in the Americas and Europe.
While the Imbokodo study did not provide sufficient protection to continue, there were no safety concerns with the Adenovirus26-based mosaic vaccine candidate. The Ad26 platform delivers a protein, known as an antigen, to stimulate an immune response. The platform has proven effective in other successful vaccines, including for Ebola and COVID-19. There is every reason to have confidence in the effectiveness of the Ad26-based Ebola and COVID-19 vaccines that have been important in helping to curb Ebola outbreaks and blunt the current COVID-19 pandemic. It is important to remember it is not the platform that provides protection, it is the immune reaction to the antigen within the platform. Unfortunately, HIV is a particularly challenging virus that more easily evades the immune system compared to many other viruses.
“We need an HIV vaccine to provide a durable end to the HIV pandemic, but we can’t wait for a vaccine,” added Warren. “Now is the time to go all in on providing comprehensive HIV prevention options that already exist and the programs needed to support people in using their chosen options, while also re-engaging in vaccine research. If we’ve learned one lesson from the COVID-19 response, it is that political will, sufficient funding and unprecedented cooperation in the face of a global threat is possible. HIV has been for decades — and remains — a global threat; it is past time to act boldly to confront it.”
###
About AVAC: Founded in 1995, AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive response to the pandemic. Follow AVAC on Twitter @HIVpxresearch.
IAS 2021: Our take and updates
COVID-19 may have forced some limiting factors onto the 11th IAS Conference on HIV Science—the conference was primarily online; the attendance was lower; and we couldn’t interact with our colleagues face-to-face—but moving in and out of virtual sessions, something transformative was in the air. The intersection of the responses to COVID-19 and HIV and the glaring disparities in health made ever more undeniable by COVID-19, are giving new meaning and momentum to changes advocates have been pressing for years, even decades. Where to begin…
- DSD: The time is now
- The latest on the prevention pipeline
- And vaccines?
- COVID-19 and HIV
- PrEP and resistance
- Calls for people-centered solutions
- New targets, old problems
DSD: The time is now
Differentiated service delivery (DSD) accelerated by orders of magnitude—telephone counseling, dispensing multi-month supplies of drugs, home delivery, community-based refills, and other innovation staved off hundreds of thousands of predicted HIV deaths, which were expected if people couldn’t get to the pharmacy or the clinic for treatment during COVID-19 lockdowns.
Multiple conference sessions referred to numerous initiatives where DSD scaled up rapidly, and with success. A few examples: An initiative from the CQUIN network coordinated among 21 different countries to share resources and lessons on DSD. PEPFAR’s Catherine Godfrey reported from a review of 52 countries that found 30 of them had scaled up and expanded eligibility for multi-month dispensing for treatment, with a 79 percent increase in the total number of people receiving a six-month supply of drugs. A different review from seven PEPFAR-supported countries, showed overall treatment interruption did not increase. And a UNAIDS analysis showed global trends in ART initiation continued despite the lockdown. Crucial to these successes, said Godfrey, were community health workers and community-based drug distribution.
These lessons from antiretroviral treatment have been applied in prevention as well. The session, Paving the road for new PrEP products: The promise of differentiated, simplified, and decentralized delivery to maximize the potential of new products, expanded the discussion on the need for innovations in PrEP delivery. Panelists at the satellite session, convened by AVAC, IAS and PATH, noted delivery must evolve as new products move through the pipeline, or years will be wasted with low uptake. Simplifying and Improving PrEP Delivery is one of four issue briefs just published by the Prevention Market Manager project and launched at the satellite, along with Reframing Risk in the Context of PrEP, Generating and Sustaining Demand for PrEP, and Next Generation M&E for Next-Generation PrEP. All echo core principles embedded in DSD: center the development of programs, policies and products in the leadership and knowledge of those who need prevention most.
This movement to DSD holds tremendous potential for prevention just as the field is poised to add powerful new prevention options to the tool kit. Data on next-generation options were also presented at IAS.
The latest on the prevention pipeline
Days before IAS began, The HealthTimes reported Zimbabwe’s approval of the monthly Dapivirine Vaginal Ring (DVR), which would be the first country to do so. Data presented at IAS on ring use from the REACH study underscore what can be achieved by tailoring the design of products and programs. REACH is a study looking at safety and adherence of oral PrEP and the ring in young women ages 16-21. Data from the study showed a marked increase in adherence to both the ring and oral PrEP among adolescent girls compared to previous studies. The key factor in the uptick? Intensive, individualized support that allowed participants to select from a menu that included text messages, weekly check-ins by phone, “peer-buddy” and adherence support groups. These findings build on evidence from other studies, including the POWER study, that adolescents greatly benefit from intensive adherence support. REACH data on preferences between the ring and oral PrEP are forthcoming.
A ring-focused session—Intravaginal options: Today and in the future—covered a lot of ground, from early-stage research on multipurpose rings for prevention, to work the World Health Organization (WHO) is doing to help facilitate the introduction of the Dapivirine Vaginal Ring. The WHO already recommends the ring and its Coordinator of Treatment and Care in the Department of HIV/AIDS, Meg Doherty, said the WHO plans to develop tools and guidance to assist countries to fit this new tool into their context, work on the supply chain, generate demand and more. These tools and guidance are expected by early 2022.
On the research front, Andrea Thurman (CONRAD) presented data from Phase I studies of a ring loaded with levonorgestrel (LNG) and tenofovir (TFV) and showed it is safe, acceptable and met benchmarks for drug levels in the body. Further research is warranted. Another presentation in that session came from Sharon Hillier (UPMC Magee-Womens Hospital), who presented highlights from the pipeline of intravaginal ring research including a three-month Dapivirine Ring and a novel MPT ring that’s both non-hormonal and includes a non-ARV-based antiviral.
A satellite session, Bringing the Dual Prevention Pill to Market: Opportunities for HIV and Pregnancy Prevention and Implications for Future Multipurpose Prevention Technologies (MPTs), reviewed the status of the Dual Prevention Pill, which could be available as early as 2024. If approved, it would be the first MPT to go to market since male and female condoms. This novel strategy provides unprecedented opportunities to integrate sexual and reproductive health (SRH) with HIV services, but major challenges must be met. The field of women’s health and family planning, policy makers and all stakeholders will need to understand why and how HIV prevention is their priority too, and how the DPP fits in the context of community health. Early, frequent and comprehensive consultations across both fields can and must serve as a model for breaking down these silos.
In a late-breaker session, Sharon Hiller presented data from the Phase 2a study of monthly oral islatravir, building on data presented earlier this year at HIVR4P. Hillier’s presentation at IAS 2021 showed this strategy met—and exceeded—key benchmarks for drug levels in the body that researchers think will be needed for it to be effective. The week-24 data also showed that it’s safe and well-tolerated. Efficacy data on this new prevention option will come from two large-scale efficacy trials (IMPOWER-22 and IMPOWER-24), results of which are expected in 2024. Islatravir is also being studied for long-term use via an implant.
And vaccines?
With a robust non-vaccine prevention pipeline, some of the vaccine session titles seemed to hint at a field wondering about its place: Will there be a next generation HIV vaccine if current ones fail?; An HIV vaccine: who needs it?; and HIV vaccines and immunotherapy: Quo vadis? (Latin for “Where are you going?”) The answer to that question is that HIV vaccine research is moving forward. Discussions at these sessions pointed to intensifying global interest in vaccine research and implementation, with COVID on everyone’s mind—and much of the success in COVID vaccines owed to the legacy of research in HIV. HIV vaccine research is moving forward with diverse approaches, and efficacy data from the two ongoing large-scale trials of Janssen’s Adeno 26-based vaccine are expected within the next two years. The AMP trials, and their implications for vaccine and antibody research, were also part of the discussion and are discussed in more detail in our recent document, Understanding Results of the AMP Trials.
But this momentum can’t be taken for granted. As Lynn Morris, from the University of the Witwatersrand and a leading antibody researcher, said in her plenary, it’s important now to galvanize political will, support increased investment and industry involvement in HIV vaccine development, run more parallel trials and take more risk.
And no matter the challenges of vaccine science, once available people will need to take it. AVAC’s Daisy Ouya reminded attendees at a UNAIDS/HIV Vaccine Enterprise satellite session that early and consistent community engagement is essential. If the field is going to reach coverage targets, community mistrust can’t be a barrier.
COVID-19 and HIV
A WHO report found HIV is a risk factor for severe or critical COVID-19. The WHO Global Clinical Platform for COVID-19 drew data from 24 countries and more than 15,000 people. This report offers another picture on HIV and COVID from the largest pool of data to date compared to other smaller studies that did not find a link, including one from the US, also presented at IAS 2021. The results have reinforced the need to ensure people living with HIV are listed as priority populations to receive COVID vaccines across the globe. This must happen in the context of massive scale-up to produce and distribute vaccines and close the gap in vaccination between the global north and south.
PrEP and resistance
The GEMS project monitored for the development of drug resistance among PrEP-takers. The project analyzed samples from 104,000 people from PrEP programs in Eswatini, Kenya, South Africa and Zimbabwe. There were 229 documented seroconversions overall and 118 were sequenced (some participants didn’t provide samples and some samples had low viral load and couldn’t be sequenced). Of those 118, 23 percent had HIV with a PrEP-associated mutation for drug resistance. Urvi Parikh, Senior Project Advisor of GEMS, presented the data and put the findings in context: the number of reported infections while on PrEP was very small, and an even smaller number had resistant mutations.
Based on the GEMS data, the most common mutation, M184V/I, is not expected to undermine the efficacy of one of the most important treatments across Africa, dolutegravir-based regimens. It will be important to monitor where these mutations will affect future treatment. It will also be vital to carefully screen for HIV among people who want PrEP in order to catch early infections that could lead to resistance. For additional background, our colleague Gus Cairns did a terrific summary of these findings as part of the NAM/AIDSMAP reports throughout the conference.
Calls for people-centered solutions
IAS 2021 heard an emphasis on the importance of community-led, client-controlled empowerment and leadership, which starts at the beginning of the research process, framing the questions that must be answered and how to answer them.
No Data No More: Manifesto to Align HIV Prevention Research with Trans and Gender Diverse Realities launched during IAS 2021. Developed by trans and gender-diverse (TGD) advocates from South Africa, Europe and the United States, with support and solidarity from AVAC, the manifesto demands an HIV prevention research agenda based on the priorities of TGD communities, with those communities driving decisions throughout the process.
Among the demands: provide gender-affirming hormone treatment (GAHT) across the continuum of HIV research, prevention and care; address the barriers that limit access to research and prevention for TGD people; recruit TGD researchers and other experts to design and implement solutions at all phases of the response.
At a session, What is missing in the HIV response?: Strengthening HIV programmes for trans populations in the Global South, presenters decried the absence of data on trans health outcomes even as TGD people face high risk of HIV. See US CDC statistics that show 1 in 7 (14 percent) transgender women in the United States have HIV and an estimated 3 percent of transgender men have HIV, with even less data available for non-binary individuals.
Liberty Matthyse of Gender Dynamix in South Africa said “trans and gender-diverse healthcare is greatly understudied,” fundamentally undermining the effort to end the epidemic. “We need to prioritize community-led participatory research, plug into existing community-led movements, co-create context-specific methodology to reach missing and undocumented cases. And we need to decentralize access to hormonal care and make it part of a package of HIV services. Every person should have the right to gender self-determination.”
Rena Janamnuaysook’s presentation at this session provided a model. At Thailand’s Tangerine Clinic, members of the trans community identified priority health needs, co-designed a program of services, and received training to deliver qualified care. About 4,000 community members rely on the clinic, which offers hormone services and other gender-affirming care as an anchor to generate demand for other health services including HIV testing, prevention and treatment. Nearly all (94 percent) of the 10 percent who have tested positive have initiated ART, nearly all of them (97 percent) are virally suppressed, and 18 percent of those who have tested negative initiated PrEP. “Key populations-led services increased access to testing, simplified services, and promoted a sustainable HIV response,” said Rena.
New targets old problems
These stories from IAS 2021 put the past year in perspective. The science that was needed to respond to both SARS-CoV2 and HIV has seen significant advances and must continue. The innovation to deliver treatment and prevention has also seen unprecedented effort, and must accelerate and expand. But policy and political will has failed to close gaping inequities that mean, among other things, the 3.3 billion doses of COVID vaccine delivered to date are concentrated in a few wealthy countries, that lockdown drove up reports of rape in Uganda by 24 percent while the use of PEP dropped by 17 percent, that 150 million people will fall into extreme poverty this year, that COVID remains a threat to global health everywhere.
The new UNAIDS targets, the so called “10’s” aimed at social factors that drive epidemics (punitive laws and policies, stigma, discrimination and gender-based violence) should galvanize action from every quarter. Approved by the UN’s High Level Meeting on HIV in June, these new targets must be used to build on the sweeping changes underway in 2020, to dismantle structural barriers and to embrace new evidence-based models that will make prevention a reality everywhere it’s needed.
Research Literacy Zone Roundup
Alongside last week’s IAS 2021 Conference, AVAC and partners hosted a range of dynamic sessions in the virtual Research Literacy Zone, where researchers and advocates explored timely topics including: Dapivirine Vaginal Ring rollout, advances in vaccine and cure research, U=U, new approaches to understanding social factors that impact health, vaccine hesitancy and more. The Zone is a gathering place for researchers and community advocates to dive deep on critical topics in a small-scale environment.
All Zone sessions are available on our Research Literacy Zone page and on ENGAGE, AVAC’s online platform for peer-to-peer resource-sharing and collaborative learning. Register for your free account today, join the conversation, and access all that ENGAGE has to offer.
Also, the Zone isn’t just for conferences! AVAC hosts virtual events and conversations throughout the year (including an August 11 rectal microbicides webinar with AFC!). Have a topic idea for a future session? Drop us a note!
RESEARCH LITERACY ZONE @ IAS 2021
- HIV Cure Research in Africa: Challenges and Opportunities
- Pushing U=U Jigsaw Puzzle into the HIV Prevention Agenda
- Models, Maps and Measures: What advocates need to know about new strategies assessing social determinants
- A Conversation with Advocates on Vaccine Hesitancy
- Inclusion of Pregnant and Breastfeeding Women in HIV Prevention Research: What can you and I do to move this agenda forward
- Ring Roundup
HIV Cure Research in Africa: Challenges and opportunities included a panel of researchers and advocates exploring some of the challenges and opportunities of HIV cure research on the African continent, strategies that are currently being pursued, and the science of the cases of HIV cure reported in the news. Listen to the recording.
Pushing U=U Jigsaw Puzzle into the HIV Prevention Agenda focused on efforts to use the science of U=U to promote HIV treatment uptake, enhance adherence and eliminate stigma and discrimination, so that PLWHIV can live longer and have healthy relationships while protecting their partners from contracting HIV. Listen to the recording.
Models, Maps and Measures: What advocates need to know about new strategies assessing social determinants focused on how to assess the social determinants of HIV and a special NIH-funded initiative on the issue. The expanding pipeline for HIV prevention was one of the driving factors motivating the NIH to fund an initiative examining new ways of measuring social determinants.. The discussion focused on two new strategies: using models to determine what factors enhance the effectiveness of cash transfers in adolescent girls and young women in South Africa, and the use of GPS tracking to determine barriers to PrEP access in young MSM in NYC. Listen to the recording.
A Conversation with Advocates on Vaccine Hesitancy provided attendees a space to reflect on the urgent need for vaccine equity and potential vaccine hesitancy. Panel members discussed why some individuals are hesitant in their communities. The discussion also focused on solutions, with panel members and participants sharing what has worked in their contexts and resources they are developing to engage communities in the discussion now. Listen to the recording.
Inclusion of Pregnant and Breastfeeding Women in HIV Prevention Research: What can you and I do to move this agenda forward centered on the importance of including pregnant and breastfeeding women in HIV prevention trials. The discussion outlined barriers to participation and implementation and focused on steps to move the field forward. Listen to the recording.
Ring Roundup covered updates in the research program and rollout plans for the Dapivirine Vaginal Ring (DVR). Attendees learned about IPM’s DVR research program and the early-phase research pursuing a longer-acting formula and dual prevention (HIV and pregnancy). Discussion also focused on the current regulatory approval process of the ring as a prevention option for women and the steps advocates can take to secure national approvals. Listen to the recording.
Stay tuned for our full roundup of IAS conference news later this week, and remember, check out ENGAGE for future events and conversations, and let us know if you have an idea to share!
HIV Vaccines: The basics
This introductory PowerPoint slide set reviews basic concepts, and provides an overview of research status and recent developments.
How to be #HIVvaccineaware this #HVAD2021
Today, May 18th, is HIV Vaccine Awareness Day (HVAD), and advocates are calling for policies, science and advocacy for HIV vaccines that leverage the lessons of the past year.
This HVAD, we are focused on how the COVID experience can speed the development AND delivery of vaccines for HIV, TB, malaria and other diseases. Below you’ll find a roundup of resources, from AVAC and others, providing context, key messages and other information on what the field has learned from COVID-19, the essential role of vaccines in global health, and what’s next in the search for an HIV vaccine.
Vaccines & Global Health in Perspective
- In a commentary today in Bhekisisa, Fatima Hassan of Health Justice Initiative and AVAC’s Mitchell Warren outline Finding an HIV vaccine: Five lessons from the response to COVID-19.
- Episode 1 of the new podcast from the International AIDS Society (IAS), HIV Unmuted takes listeners to the global HIV change-makers who have shaped the response and asks what must happen now to end the AIDS epidemic. This debut episode features the NIH’s Anthony Fauci, AVAC’s Maureen Luba, Udom Likhitwonnawut from Thailand’s National Community Advisory Board, and others.
- In their piece, How HIV Vaccine Advocacy Can Leverage Lessons from COVID-19, USAID’s Ashley Lima and Margaret McCluskey draw on the experiences and perspective of CASPR partners and their agenda for vaccine advocacy in the midst of COVID.
AVAC’s HVAD Package
Check out AVAC’s key messages for this HVAD. Designed for easy communication, this resource outlines the six ways that the COVID experience can shape HIV vaccine advocacy moving forward. For social media, we hope our sample tiles and tweets will inspire action to keep audiences #HIVvaccineaware this #HVAD2021. Download tiles 1, 2, 3, 4, 5, 6. Get the basics with AVAC’s annually updated powerpoint tutorial on HIV vaccines; current and planned vaccine research with this table of clinical trials; and our infographics gallery allows you to search by prevention intervention. All of these resources and more are up at www.avac.org/hvad.
IAVI’s HVAD Resources
We encourage you to explore IAVI’s #HVAD2021 toolkit for the perspectives of scientists and community liaison teams, videos on the science and development of vaccines, and tiles and tweets supporting their HVAD campaign at #EyesOnTheTarget and more.
Updates from the Field
- Earlier today, WACI Health and AfNHI hosted a webinar exploring the remarkable advances in HIV vaccine research and the promising concepts being studied today with Ntando Yola, of APHA-South Africa and the Desmond Tutu Health Foundation, and Nyaradzo Mgodi, clinical pathologist from the University of Zimbabwe. Look for a recording of the webinar here, along with recordings of two additional webinars: one co-hosted by IAVI and KANCO featuring leading researchers and advocates in East Africa and one co-hosted by IAVI and SANAC featuring leaders in South Africa.
- On May 13th, AVAC hosted a webinar HIV Vaccines in the Midst of COVID. In this recording you’ll hear researchers and advocates discussing new vaccine technologies, delivery challenges, community engagement, and confidence in both vaccines and vaccine research.
- In the latest episode of AVAC’s Px Pulse podcast, Dive into the AMP Trials, we unpack the results of the recent Antibody-Mediated Prevention (AMP) studies, which will inform the fields of antibodies-for-prevention, and HIV vaccine research.
We can make #HVAD2021 the turning point, when the full potential of vaccines becomes undeniable, and the world renews its commitment to the search for vaccines for HIV, TB and other diseases that continue to threaten so many people’s health and well-being.
On this HIV Vaccine Awareness Day, leveraging the lessons of COVID to advance an HIV vaccine
This HIV Vaccine Awareness Day—observed each year on May 18—takes place in a new era of vaccine science. Accelerated by the knowledge, technologies, networks and community engagement models developed for HIV, the search for COVID-19 vaccines produced extraordinary results in record time. COVID demonstrated that a global sense of urgency to end a pandemic can produce ample research money overnight, help pharmaceutical companies, academic institutions, and nonprofits overcome previously insurmountable barriers to collaboration, and shrink vaccine development and testing timelines from decades to months. And yet, the results of those innovations are not translating quickly or equitably enough to end this pandemic. Advances in scientific R&D can’t have impact without equally robust investment in and commitment to delivery.
AVAC’s theme for HVAD 2021 is “HIV Vaccine Research: Building on Lessons from COVID”. We are focused on how the COVID experience can speed the development AND delivery of vaccines for HIV, TB, malaria and other diseases. Visit our dedicated HVAD 2021 page for resources to help make sense of this unique moment in vaccine history, and to build a global vaccine advocacy agenda for the future. There you’ll find:
The 2021 HVAD toolkit:
- Key Messages: Designed for easy communication, the HVAD 2021 messages outline the six ways that the COVID experience can shape HIV vaccine advocacy moving forward.
- Social media tiles: Sample tiles and tweets to inspire action to keep audiences #HIVvaccineaware this #HVAD2021.
- Updated HIV Vaccines 101 PowerPoint presentation.
The page also has links to:
- A recording of yesterday’s webinar, HIV Vaccines in the Midst of COVID, featuring HIV vaccine researchers and advocates Barney Graham (NIH Vaccine Research Center), Definate Nhamo (PZAT), Linda-Gail Bekker (Desmond Tutu Health Foundation), Matthew Rose (Health GAP) and Pontiano Kaleebu (MRC/UVRI & LSHTM Uganda Research Unit), discussing new vaccine technologies, delivery challenges, community engagement, and confidence in both vaccines and vaccine research.
- A new episode of our Px Pulse podcast, Dive into the AMP Trials, which helps explain the results of the recent Antibody-Mediated Prevention (AMP) study and what it could mean for HIV vaccines.
- Clinical Trials Update – A table of past, current and planned vaccine trials.
- Infographics gallery – Search by intervention—antibody-mediated prevention or HIV vaccine—for all the latest infographics.
The opportunities and challenges brought to light by COVID make this an HIV Vaccine Awareness Day like no other. This #HVAD2021, we must all become #HIVvaccineaware and ensure new vaccines get developed and delivered!
HIV Vaccine Research: Building on the Lessons from COVID
Building on the lessons of COVID, HIV vaccine advocates can mobilize for an HIV vaccine research and access agenda. This two-page document gives suggested messaging.
Breaking the Bottlenecks to COVID-19 Vaccine Access
This graphic identifies the factors contributing to the bottlenecks in the global supply of COVID-19 vaccines.